Skip to contentH
Hepion Pharmaceuticals, Inc.
H
HEPAHepion Pharmaceuticals, Inc. Q2 2020 · 10-Q
Revenue$0.00$0.00no prior Q2 2019 on file Net Income-$4.94M-$4.94MN/M vs Q2 2019 EPS Diluted-$0.58-$0.58N/M vs Q2 2019 Operating Income-$4,775,414N/M Operating Cash Flow
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Hepion Pharmaceuticals, Inc. · CIK 1583771 · Engraved from SEC EDGAR
derived
Free Cash Flowderived-$3,122,790N/M ended Jun 30, 2020 · filed Aug 12, 2020 · 43 d after period end